Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer.

Biomolecules·2026
Same author

Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.

Oncogene·2026
Same author

Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity.

Cancer research·2025
Same author

EC359 Enhances Trametinib Efficacy in <i>Ras</i>/<i>Raf</i>-Driven Ovarian Cancer by Suppressing LIFR Signaling.

Biomolecules·2025
Same author

Ligand-receptor interactions induce and mediate regulatory functions of BATF3<sup>+</sup> B cells.

Science advances·2025
Same author

Role of DENN Domain-Containing Protein 5b (dennd5b) during early embryonic development of zebrafish.

Molecular biology reports·2025

Related Experiment Video

Updated: Jan 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

The PELP1 Pathway and Its Importance in Cancer Treatment.

Khaled Mohamed Nassar1, Panneerdoss Subbarayalu2, Suryavathi Viswanadhapalli1

  • 1Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.

Biomolecules
|December 30, 2025
PubMed
Summary

Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is an oncogene implicated in various cancers. This review highlights PELP1

Keywords:
PELP1PELP1 inhibitorsRix complexoncogene

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a proto-oncogene functioning as a nuclear and cytoplasmic scaffolding protein.
  • PELP1 is crucial in processes including nuclear receptor signaling, ribosome biogenesis, chromatin modifications, cell cycle progression, non-genomic signaling, and DNA damage response.
  • Elevated PELP1 expression correlates with poor prognosis in breast, ovarian, endometrial, prostate, and liver cancers.

Purpose of the Study:

  • To review recent advancements in PELP1 biology.
  • To focus on PELP1's oncogenic functions and potential therapeutic inhibitors for cancer treatment.

Main Methods:

  • Literature review of recent studies on PELP1.
  • Analysis of PELP1's structural motifs, scaffolding function, and oncogenic activity.
  • Examination of emerging therapeutic strategies targeting PELP1.

Main Results:

  • PELP1's multifaceted roles in cancer development and progression are elucidated.
  • PELP1's potential as a therapeutic target is supported by its oncogenic activity.
  • Emerging inhibitors show promise for PELP1-targeted cancer therapy.

Conclusions:

  • PELP1 is a significant proto-oncogene with broad implications in multiple cancer types.
  • Targeting PELP1 presents a promising avenue for novel cancer therapeutics.
  • Further research into PELP1 inhibitors is warranted for effective cancer treatment.